Last reviewed · How we verify
CSs
CSs likely refers to corticosteroids, which suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
CSs likely refers to corticosteroids, which suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders, Allergic reactions, Respiratory conditions (asthma, COPD).
At a glance
| Generic name | CSs |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Inflammation |
| Phase | FDA-approved |
Mechanism of action
Corticosteroids are a broad class of anti-inflammatory and immunosuppressive agents that work by translocating to the nucleus and modulating gene expression of inflammatory mediators. They reduce immune cell activation, decrease cytokine production, and stabilize cell membranes to reduce inflammation across multiple tissues.
Approved indications
- Inflammatory and autoimmune disorders
- Allergic reactions
- Respiratory conditions (asthma, COPD)
- Rheumatologic diseases
Common side effects
- Immunosuppression / increased infection risk
- Hyperglycemia
- Osteoporosis (with chronic use)
- Hypertension
- Mood changes / psychiatric effects
- Adrenal suppression
Key clinical trials
- Wireless Assessment of Respiratory and Circulatory Distress - Europe (NA)
- CSS-SR Validation Study
- Validation of a Prognostic Method for Assessing the Risk of Distant Metastasis in Early-stage Breast Cancer
- Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
- Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
- One-Time DNA Study for Vasculitis
- VCRC Tissue Repository
- Central Sensitization Syndromes and Post-Traumatic Stress in Women: Psychological Profile and Intervention (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSs CI brief — competitive landscape report
- CSs updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI